Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

Plain-language summary

Background Cases of early-onset Alzheimer disease (AD) with an autosomal dominant inheritance pattern (familial AD [FAD]) are rare but have greatly advanced our understanding of the molecular pathogenesis of AD. We describe herein a kindred with very early-onset FAD (age, Objective To analyze the neuropathological and genetic features of a family with onset of AD in the third decade of life. Design, setting, and participants The proband underwent full clinical assessment and postmortem examination at the Washington University Alzheimer's Disease Research Center, St Louis, Mo.

What this study adds

Evidence grade: Low

This case report describes a novel presenilin 1 mutation (S170F) causing Alzheimer's disease with Lewy bodies in the third decade of life in one family. It is a genetic and neuropathological description, not a treatment study, so it does not show how to treat, cure or prevent the disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Snider, B. J., Norton, J., Coats, M. A., Chakraverty, S., Hou, C. E., Jervis, R., et al. (2005). Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Archives of neurology. https://doi.org/10.1001/archneur.62.12.1821

Vancouver

Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, et al. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Archives of neurology. 2005. doi:10.1001/archneur.62.12.1821. PMID: 16344340.

BibTeX

@article{snider2005-16344340,
  author  = {Snider, B. J. and Norton, J. and Coats, M. A. and Chakraverty, S. and Hou, C. E. and Jervis, R. and Lendon, C. L. and Goate, A. M. and others},
  title   = {{Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life}},
  journal = {Archives of neurology},
  year    = {2005},
  doi     = {10.1001/archneur.62.12.1821},
  pmid    = {16344340},
  url     = {https://doi.org/10.1001/archneur.62.12.1821}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This case report describes a novel presenilin 1 mutation (S170F) causing Alzheimer's disease with Lewy bodies in the third decade of life in one family. It is a genetic and neuropathological description, not a treatment study, so it does not show how to treat, cure or prevent the disease.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 2 of 5; Impact for its field and year 2 of 6; Cited by studies here 3 of 6; Still being cited 1 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 46 of 100.46 of 100 points earned54 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Archives of neurology)
Journal's citation record 3 / 4 Archives of Neurology: journal h-index 353 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2005 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 130 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.7 citations a year over 23 year(s) since 2005
Impact for its field and year 2 / 6 Cited 2.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 10 other studies in this library
Still being cited 1 / 4 Cited 11 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author John C. Morris: h-index 209 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 16344340)
Free to read 0 / 2 Behind a paywall — scores zero
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Risk genes beyond APOE from nearby years

Also tagged “precursor”

1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →